EGFR and non-small cell lung carcinoma: Clinical trial evidence indicates that osimertinib, a 3rd generation EGFR-TKI developed to overcome the resistance of T790M, is effective (~70% response rate) in treating NSCLC patients who had acquired resistance to 1st and 2nd generation EGFR-TKIs because of the development of the T790M mutation [32,33].